EUCTR2006-001168-22-ES进行中（未招募）1 期
Estudio de fase II, aleatorizado, abierto y controlado para evaluar la seguridad e inmunogenicidad de diferentes formulaciones de una vacuna experimental frente a la gripe pandémica (formulación con virus fraccionados adyuvada en AS03) administrada con un esquema de dos dosis (intervalo de 21 días) en niños de entre 3 y 9 años de edad.A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age. - H5N1-009, H5N1-022 STG 009 cohort 2, H5N1-023 STG 009 cohort 3
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 405
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Children who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •Children aged between and including 3 and 9 years of age at the time of first vaccination.
- •Written informed consent obtained from the parent or guardian of the subject.
- •Healthy children as established by medical history and history-directed clinical examination before entering the study.
- •Subjects who are likely to reside in the vicinity of the study center for the duration of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the H5N1 vaccine candidate within 30 days prior to the enrolment in this study, or planned use during the study period.
- •Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination, with the exception of routine childhood inoculations which cannot be delayed, but which must not be administered on the same day as the H5N1 vaccine candidate.
- •Administration of the interpandemic influenza vaccine 21 days prior to Day 0 or up to Day 51.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the enrolment in this study. (For corticosteroids, this will mean prednisone, or equivalent, <= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- •Any chronic drug therapy to be continued during the study period, with the exception of inhalative treatment for seasonal allergies or asthma.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.
- •History of hypersensitivity to vaccines.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines such as egg protein or thiomersal.
- •History of any neurological disorders or seizures.
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature <37.5°C).
- •Administration of immunoglubulins and/or any blood products within the three months prior to the enrolment in this study or planned during the study.
- •Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study.
研究者
相似试验
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, abierto (con grupos de control enmascarados de activador del plasminógeno y placebo) para evaluar los efectos de distintos regímenes de infusión intratrombo de plasmina (humana) en comparación con activador del plasminógeno y placebo en pacientes con oclusión aguda de una arteria nativa de las extremidades inferiores o de un injerto de derivacióEUCTR2010-019760-36-ESTalecris Biotherapeutics, Incorporated100
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, abierto y multicéntrico, que compara el tratamiento con bevacizumab más RAD001 frente a interferón alfa-2a más bevacizumab en el tratamiento de primera línea de pacientes con carcinoma renal metastásico de células clarasA randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidneyPacientes con carcinoma renal metastásico de células clarasPatients with metastatic clear cell carcinoma of the kidneyMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-000077-38-ESovartis Farmacéutica S.A360
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, abierto, multicéntrico, de comparación de AUY922 con docetaxel o irinotecán en pacientes adultos con cáncer gástrico avanzado y en progresión tras una línea de quimioterapiapacientes adultos con cáncer gástrico avanzado y en progresión tras una linea de tratamientoMedDRA version: 12.1Level: PTClassification code 10017758Term: Gastric cancerEUCTR2009-015407-47-ESovartis Farmacéutica, S.A.120
进行中（未招募）
1 期
Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) (A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC)) - CONCERTEUCTR2007-005083-28-ESBayer Healthcare AG, Leverkusen
进行中（未招募）
1 期
Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapia FOLFIRI en sujetos con cáncer colorrectal con KRAS no mutado y metástasis solo hepáticas. - PLANETEUCTR2008-006766-28-ESGrupo de Tratamiento de los Tumores Digestivos - TTD80